TX-2060
2-nitroimidazole-sodium borocaptate-10B conjugate used as a 10B-carrier in boron neutron capture therapy; structure in first source
Networked: 1
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Hiraoka, Masamitsu:
1 article
(09/2004)
|
| 2. | Hori, Hitoshi:
1 article
(09/2004)
|
| 3. | Kinashi, Yuko:
1 article
(09/2004)
|
| 4. | Maruhashi, Akira:
1 article
(09/2004)
|
| 5. | Masunaga, Shin-Ichiro:
1 article
(09/2004)
|
| 6. | Nagasawa, Hideko:
1 article
(09/2004)
|
| 7. | Nagata, Kenji:
1 article
(09/2004)
|
| 8. | Ono, Koji:
1 article
(09/2004)
|
| 9. | Sakurai, Yoshinori:
1 article
(09/2004)
|
| 10. | Suzuki, Minoru:
1 article
(09/2004)
|
Related Diseases
| 1. | Neoplasms (Cancer)
09/01/2004
- " Based on the data of the pharmacokinetics analyses, TX-2060 was chosen for a subsequent tumor-irradiation study. " 09/01/2004
- " 10B-carrier, with a gamma-ray-sensitizing effect on tumor cells as well as the potential to keep 10B in tumors and sensitize tumor cells more markedly than conventional 10B-carriers, such as TX-2060, is a promising candidate for use in BNCT." 09/01/2004
- " Further, TX-2060 clearly exhibited a radio-sensitization effect with gamma-rays, not only on total cells but also on Q and hypoxic tumor cells, which was not achieved by BSH. " 09/01/2004
- " In addition, TX-2060 had a significantly stronger radio-sensitization effect with reactor thermal neutron beams than BSH on both total and Q cells in solid tumors. " 09/01/2004
- " 10B distribution analyses in tumors, muscles, blood and liver indicated that TX-2060 has the most favorable characteristics for concentrating a sufficient amount of 10B in tumors and maintaining a high enough 10B concentration during irradiation. "
|
|
Related Drugs and Biologics